Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7449 (Stenoparib) in Advanced Solid Tumors and B-cell Malignancies
NCT01618136Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2012
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of stenoparib in solid tumor, B cell malignancies, ovarian cancer and 2 more (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Tolerated Dose of E7449 as Single Agent at 24 months, Maximum Tolerated Dose of E7449 in Combination with TMZ at 24 months and 1 more. Started Jan 2012; status: completed.
02
Drugs
stenoparib
03
Conditions
solid tumorB cell malignanciesovarian cancermelanomatriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01618136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01618136.